All News

RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
CAR T on purple background

How many CAR-T’s do we need to test drive?

Janet Pope, MD, MPH, FRCPC

CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.

Read Article
psoriasis,arm,hand,rash,elbow

Synovio-entheseal inflammation and the tipping point from PsO to PsA

Antoni Chan, MD, PhD

Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. A study presented at EULAR 2026 provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific imaging features that distinguish patients whose arthralgia is progressing toward arthritis from those who remain stable.

Read Article
Eular stage

What’s New in Macrophage Activation Syndrome Therapeutics

Bella Mehta, MBBS, MS

MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.

Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush RheumNow ( View Tweet)
What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9
Dr. John Cush RheumNow ( View Tweet)
RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Links:

Dr. John Cush RheumNow ( View Tweet)
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv

Links:

Dr. John Cush RheumNow ( View Tweet)
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress. https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Topic Panel: EULAR 2026 Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071 https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2026 RA Topic Panel https://t.co/lLSL6FW9sg

Links:

Dr. John Cush RheumNow ( View Tweet)

New: Classification Criteria and Recommendations in SpA ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp
Dr. John Cush RheumNow ( View Tweet)
Improving Referrals for Inflammatory Arthritis Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu

Links:

Dr. John Cush RheumNow ( View Tweet)
Day 3 Recap: EULAR 2026 Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288 https://t.co/TSnVVOpF75 https://t.co/EFD0WKRpF4

Links:

Dr. John Cush RheumNow ( View Tweet)
Day 2 Report from EULAR 2026 Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2 https://t.co/6KwtkMNLAf https://t.co/Toh4HNZFN5

Links:

Dr. John Cush RheumNow ( View Tweet)
Are we failing in the treatment of RA-ILD? Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026. https://t.co/3UpQQE22Nz https://t.co/ULdCOgh7pY

Links:

Dr. John Cush RheumNow ( View Tweet)
MRI as a novel biomarker in lupus The clinical abstract sessions at #EULAR2026 on diagnostic tools in lupus showcased interesting studies, including the use of MRI, as potential non-invasive biomarkers. https://t.co/TK2gqSxAg5 https://t.co/5Qj8KXWgub

Links:

Dr. John Cush RheumNow ( View Tweet)
Making Methotrexate More Effective Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×